(Incidence, Treatments, Key Companies, Pipeline and Trends)

Transcription

1 World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends) CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION Overview Structural Organization of the Neurological System o Central Nervous System o The Brain Aging and Alzheimer s Disease Stages of Alzheimer s Disease Risk Factors Life Expectancy and the Growing Incidence of Alzheimer s Disease World Demographics Prevalence, Incidence and Mortality Insurance for the Elderly in the United States Generic Competition o Teva/Mutual Pharmaceutical/United Research Laboratories and Eisai o Dr. Reddy s and Novartis o Ranbaxy and Ortho-McNeil Neurologics CHAPTER THREE: ALZHEIMER S DISEASE PRODUCT ANALYSIS Overview of Products Aricept Namenda/Exiba/Axura Exelon Razadyne Other Products CHAPTER FOUR: RESEARCH AND DEVELOPMENT Overview Phase III o AAB-001

2 o Aricept SR o Exelon Transdermal Patch (ONO 2540) o Flurizan o LY o Memryte o Namenda Once-Daily o Rosiglitazone XR o Xaliproden Phase II o Dimebon o AC-1202 o Ispronicline o MEM-3454 o MEM-1003 o AN-1792 o ABT-089 o ACC-001 and QS-21 o AL-108 o CX717 o ELND-005 o Huperzine A o Immune globulin, intravenous o LY o Lecozotan SR o MK-0249 o MK-0952 o Neramenxane o NIC5-15 o PRX o Rasagiline mesylate o SAM-531 o SGS742 o T 817 MA o TTP 488 Phase I o o Aricept Transdermal Patch o AV 965 o AVE 8112 o Bapineuzumab o CAD-106 o CERE-110

3 o CTS o EVP 6124 o GSI 953 o Lecozotan SR o MEM-1414 o NGX267 o Oxigon o Paz-417 o PF o PF o R1450 o R4996/MEM o SSR o V 950 Preclinical Development o TTP 4000 o AAB-002 o Alzhemed o BACE Inhibitors (TTP 854) o CX1739 o E2012 o Gamma-secretase inhibitor o GSI-136 o MEM-1917 o MPI o PBT2/PBT3/PBT4 o SAR CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS Market Overview Market Analysis by Product Type Market Analysis by Country Competitive Analysis Leading Products CHAPTER SIX: LEADING MANUFACTURERS Overview Eisai Co., Ltd. Forest Laboratories H. Lundbeck A/S Johnson & Johnson Merz Pharma GmbH

4 Novartis AG Pfizer, Inc. APPENDIX: LIST OF MAJOR COMPANIES LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY Figure 1-1: Alzheimer s Disease Market Analysis: CHAPTER TWO: INTRODUCTION Table 2-1: Alzheimer s Disease Stages 1-7 and Descriptions Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2006 Figure 2-1: Average Life Expectancy in Years by Country 1980, 2004 and 2006 Table 2-3: World Population by Selected Geographical Region, Figure 2-2: World Population by Selected Geographical Region, Table 2-4: Estimated World Population by Age and Geographical Region, 2007 Figure 2-3: Estimated World Population by Age and Geographical Region, 2007 Table 2-5: Percent Population Over 65 by Year and Region Figure 2-4: Estimated World Population by Age, 2007 and 2050 Table 2-6: Estimated Prevalence, Incidence and Mortality for Alzheimer s Disease* by Region/Country, 2007 Figure 2-5: Estimated World Prevalence and Incidence of Alzheimer s Diseases by Region, 2007 Figure 2-6: World Prevalence of Alzheimer s Disease Compared to Rest of Population Over Age 65, 2007 Table 2-7: Health Insurance Trends in the United States, Estimated 2007 (millions) CHAPTER THREE: ALZHEIMER S DISEASE PRODUCT ANALYSIS Table 3-1: Comparison of Marketed Alzheimer s Disease Treatments Figure 3-1: Alzheimer Product Sales Analysis, Figure 3-2: Aricept Sales Analysis, Figure 3-3: Namenda/Exiba/Axura Sales Analysis, Figure 3-4: Exelon Sales Analysis, Figure 3-5: Razadyne Sales Analysis, CHAPTER FOUR: RESEARCH AND DEVELOPMENT Figure 4-1: Alzheimer s Disease Treatments in Development, 2005,

5 2006, and 2007 Table 4-1: Alzheimer s Disease Therapies in Development CHAPTER FIVE: MARKET AND COMPETITOR ANALYSIS Table 5-1: Alzheimer s Disease Market Analysis, Table 5-2: Forecasted Alzheimer s Disease Market Analysis: Figure 5-1: Alzheimer s Disease Market Analysis: Table 5-3: Alzheimer s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), Figure 5-2: Alzheimer s Disease Market Analysis by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), Figure 5-3: Alzheimer s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2005 Figure 5-4: Alzheimer s Disease Market Share by Drug Type, (Cholinesterase inhibitors, NMDA antagonists), 2007 Table 5-4: Alzheimer s Disease Market Analysis by Region/Country, 2007 Figure 5-5: Alzheimer s Disease Market Analysis by Region/Country, 2007 Table 5-5: Alzheimer s Disease Market Estimated Revenues and Market Share of Leading Suppliers 2007 Figure 5-6: Alzheimer s Disease Market Estimated Market Share by Leading Suppliers 2007 Table 5-6: Alzheimer s Disease Market Estimated Sales of Top Products 2007 Figure 5-7 : Alzheimer s Disease Market Estimated Market Share of Top Products, 2007 CHAPTER SIX: LEADING MANUFACTURERS Figure 6-1: Eisai s Net Revenues and R&D Expenses for 2006 and 2007 Figure 6-2: Forest s Net Revenues and R&D Expenses for 2006 and 2007 Figure 6-3: Lundbeck s Net Revenues and R&D Expenses for 2006 and 2007 Figure 6-4: Johnson & Johnson s Net Revenues and R&D Expenses for 2006 and 2007 Figure 6-5: Merz Pharma s Net Revenues and R&D Expenses for 2006 and 2007 Figure 6-6: Novartis Net Revenues and R&D Expenses for 2006 and 2007 Figure 6-7: Pfizer s Net Revenues and R&D Expenses for 2006 and 2007

6